A drug safety physician’s alert to Dr. Peter Marks (U.S. Food and Drug Administration) regarding the need for clear guidance or regulation concerning COVID-19 vaccines as default investigational products in non-vaccine clinical trials.
ARTICLES
Voices | Voices // VaccinesA Letter to Dr Peter Marks, Food and Drug Administration
A drug safety physician’s message to Dr. Marks (U.S. FDA) regarding risk evaluation of anaphylaxis with the Pfizer-BioNTech Covid-19 Vaccine.